Current practice of launching sequentially new drugs on the global market is forgoing the pharma business hundreds of millions of dollars. OGP - Optimal Global Pricing technology is solving this problems. OGP enables a pricing function which is paralleling the drug development process. When the drug is ready to be launched the regulatory agencies have already seen/approved global pricing structure all along and the price negotiations with individual markets are cut short.

Medicines crises like the one a few years back in Greece or the current one in Romania come about mainly from misguided commercial policies that handle parallel trade improperly. Solution is Optimal Commercial Policies based on optimal global pricing plus optimal trade flows. The only technology presently available that can do that is the OGP - Optimal Global Pricing. It is resolving the economic equilibrium problem with an numerically exact optimal solution by employing a finitely converging algorithm.

Fact of life - parallel trade (PT) is legal and is the only competition to medicines under patent. The pharma industry can "learn" to live with it losing revenue or can do something about it. So far there is no good solution to parallel trade as this business of parallel trade is steadily growing. First, and so far the only, effective solution to PT is the OGP - Optimal Global Pricing technology. It is employing a finitely converging algorithm to resolve the economic equilibrium problem with optimal prices, optimal trade flows.